<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04335864</url>
  </required_header>
  <id_info>
    <org_study_id>Hydrosalpinx and ICSI</org_study_id>
    <nct_id>NCT04335864</nct_id>
  </id_info>
  <brief_title>Comparing the Impact of 2 Different Techniques in Management of Hydrosalpinx on Pregnancy Rates Following ICSI</brief_title>
  <official_title>A Clinical Trial Comparing Laparoscopic Salpingectomy Versus Hysteroscopic Proximal Tubal Occlusion on Pregnancy Rates Following ICSI (Intra-Cytoplasmic Sperm Injection) in Infertile Cases of Hydrosalpinx.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment and comparing pregnancy outcomes in hydrosalpinx patients treated by hysteroscopic
      tubal occlusion and laparoscopic salpingectomy before ICSI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hydrosalpinx has a detrimental effect on the rates of implantation, pregnancy and early
      pregnancy loss following IVF. A meta-analysis demonstrated that the implantation rate and
      clinical pregnancy rate decreased by 50% in patients with hydrosalpinx. The negative
      consequences could be due to embryotoxic properties, a decrease in endometrial receptivity,
      and hydrosalpinx fluid mechanically flushing the embryo from the uterus.

      Although laparoscopic salpingectomy and laparoscopic proximal ligation increase ongoing
      pregnancy rates in women with hydrosalpinges, those interventions are invasive and carry
      anaesthetic and surgical risks, especially in the presence of extensive adhesions, often seen
      in women with hydrosalpinges. In view of the possible adverse effects of laparoscopic
      surgery, an alternative less-invasive treatment for hydrosalpinges prior to IVF would be
      useful.

      The effectiveness of hysteroscopic tubal occlusion when compared with salpingectomy has not
      been established. Randomized clinical trials comparing both procedures prior to IVF are
      lacking.

      The present study was designed to compare hysteroscopic tubal occlusion and laparoscopic
      salpingectomy in the treatment of hydrosalpinges prior to IVF.

      This study hypothesized that in women scheduled for IVF/ICSI hysteroscopic proximal occlusion
      of hydrosalpinges would be non-inferior to laparoscopic salpingectomy in terms of ongoing
      pregnancy rates following IVF/ICSI.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical pregnancy rate following ICSI</measure>
    <time_frame>14 days after Embryo transfer</time_frame>
    <description>Defined as positive qualitative bhcg(beta human chorionic gonadotropin)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ongoing pregnancy following ICSI</measure>
    <time_frame>8 weeks after Embryo transfer</time_frame>
    <description>Defined as positive fetal heart rate on ultrasound at 8weeks gestation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Hydrosalpinx</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>39 patients with hydrosalpinx will have laparoscopic salpingectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>39 patients with hydrosalpinx will have hysteroscopic proximal tubal occlusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic salpingectomy</intervention_name>
    <description>39 patients with hydrosalpinx will have laparoscopic salpingectomy</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hystroscopic proximal tubal occlusion</intervention_name>
    <description>39 patients with hydrosalpinx will have hysteroscopic proximal tubal occlusion</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  primary or secondary infertility cases

          -  unilateral or bilateral hydrosalpinx proved by HSG (hystersalpingogram) or by
             TVUS(transvaginal ultrasound) .

        Exclusion Criteria:

          -  Uterine factor of infertility

          -  male factor of infertility

          -  preexisting ovarian pathology

          -  Presence of septic focus

          -  medical or surgical conditions that contraindicated pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shaimaa Mostafa Mohammed Refaay Elshemy[selshemy]</last_name>
    <phone>01220632263</phone>
    <email>sh.elshemy@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kasr Alainy hospital-cairo University</name>
      <address>
        <city>Cairo</city>
        <zip>11562</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kasralainy Cairo university</last_name>
      <phone>0223643351</phone>
      <email>Pg@kasralainy.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 29, 2020</study_first_submitted>
  <study_first_submitted_qc>April 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2020</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Shaimaa Mostafa Mohammed Refaay El shemy</investigator_full_name>
    <investigator_title>Principal investigator, Lecturer in obstetrics and gyneocolgy department, Cairo university</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

